PTC Therapeutics (PTCT) Insider Gregory Sells 23,749 Shares

PTC Therapeutics Insider Activity

Recent regulatory filings show activity from insider Neil Gregory Almstead at PTC Therapeutics, Inc., trading under the ticker PTCT on the NasdaqGS. The Chief Technical Operations Officer executed a series of transactions in late June 2026. On June 24, 2026, Almstead bought 5,323 shares at $38.10 apiece for a total value of $202,806.30, and also sold 5,323 shares at an average price of $85.03 under a planned sale worth $452,606.71. A few days later on June 26, 2026, he acquired another 8,130 shares at $38.10 each valued at $309,753.00, alongside a planned sale of 8,130 shares at $85.26 totaling $693,151.60.

PTC Therapeutics Stock Performance

Shares of PTCT change hands near $82.13, sitting comfortably within a 52-week trading span that stretches from a low of $57.74 up to a high of $90.87. The company holds a forward P/E ratio of 24.38. Investors keep a close eye on these price movements as the equity trades above both its 50-day moving average of $72.19 and its 200-day moving average of $72.69.

Analysts Set New Price Targets

Wall Street coverage features several recent updates from major financial institutions. On July 16, 2026, Cantor Fitzgerald maintained an overweight rating and lifted its target to $130.00 from $124.00. Wells Fargo adjusted its target on July 20, 2026, keeping an overweight rating while moving its target to $93.00 from $95.00. On July 31, 2026, Wells Fargo updated its stance again by maintaining an overweight rating and raising its target to $106.00, while Morgan Stanley kept an overweight rating with a target of $104.00. Later, on August 13, 2026, Wells Fargo reiterated an overweight rating with a $109.00 target, and Barclays maintained an overweight rating with a $122.00 target on August 14, 2026. Cantor Fitzgerald later kept an overweight rating on September 22, 2026, while bumping its target to $137.00. Most recently, RBC Capital maintained a sector perform rating on October 8, 2026, while adjusting its target to $75.00 from $85.00. Overall, the stock carries a consensus buy recommendation from 14 analyst opinions, with a mean price target of $101.79.

What PTC Therapeutics Does

Headquartered in Warren, New Jersey, PTC Therapeutics is a biopharmaceutical enterprise focused on discovering, developing, and commercializing treatments for patients dealing with rare disorders. Its portfolio includes therapies for conditions such as Duchenne muscular dystrophy, aromatic l-amino acid decarboxylase deficiency, and spinal muscular atrophy, alongside a clinical pipeline targeting various other rare conditions.

What's Ahead for PTC Therapeutics, Inc.

Market participants await the company's next earnings report, which is scheduled for release on November 5, 2026. Further updates will rely on subsequent insider filings and corporate disclosures.